ES2070107T1 - Ensayo de antigeno especifico de prostata (psa) libre o complejado. - Google Patents

Ensayo de antigeno especifico de prostata (psa) libre o complejado.

Info

Publication number
ES2070107T1
ES2070107T1 ES91913019T ES91913019T ES2070107T1 ES 2070107 T1 ES2070107 T1 ES 2070107T1 ES 91913019 T ES91913019 T ES 91913019T ES 91913019 T ES91913019 T ES 91913019T ES 2070107 T1 ES2070107 T1 ES 2070107T1
Authority
ES
Spain
Prior art keywords
free
aep
assay
complex
psa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES91913019T
Other languages
English (en)
Other versions
ES2070107T5 (es
ES2070107T3 (es
Inventor
Hans Lilja
Ulf-Hakan Stenman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STENMAN ULF HAKAN
Original Assignee
STENMAN ULF HAKAN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20380033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2070107(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by STENMAN ULF HAKAN filed Critical STENMAN ULF HAKAN
Publication of ES2070107T1 publication Critical patent/ES2070107T1/es
Application granted granted Critical
Publication of ES2070107T3 publication Critical patent/ES2070107T3/es
Publication of ES2070107T5 publication Critical patent/ES2070107T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SEGUN EL METODO DE LA INVENCION, SE APLICAN INMUNOENSAYOS PARA MEDIR EL AEP LIBRE ASI COMO UN COMPLEJO INHIBIDOR DE LA PROTEINASA. SEGUN LA INVENCION, EL AEP LIBRE Y EL COMPLEJO AEP SE MIDEN MEDIANTE UN INMUNOENSAYO NO COMPETITIVO UTILIZANDO, AL MENOS, DOS ANTICUERPOS MONOCLONALES DISTINTOS. LA INVENCION SE CARACTERIZA ADEMAS EN TANTO QUE EL COMPLEJO INHIBIDOR DE LA PROTEINASA DE INTERES SE FORMA BIEN CON UNA O1-ANTIQUIMOTRIPSINA, UN INHIBIDOR O1-PROTEASA (IAP) BIEN CON UNA O2-MACROGLOBULINA. ADEMAS, LA INVENCION SE CARACTERIZA EN TANTO QUE EL AEP LIBRE, EL COMPLEJO INHIBIDOR DE PROTEINASA-AEP Y SU RELACION SE APLICAN EN EL DIAGNOSTICO DE PACIENTES CON CANCER DE PROSTATA.
ES91913019T 1990-07-23 1991-07-22 Ensayo de antigeno especifico de la prostata (psa) libre y complejado. Expired - Lifetime ES2070107T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9002480A SE9002480D0 (sv) 1990-07-23 1990-07-23 Assay of free and complexed prostate-specific antigen
SE9002480 1990-07-23

Publications (3)

Publication Number Publication Date
ES2070107T1 true ES2070107T1 (es) 1995-06-01
ES2070107T3 ES2070107T3 (es) 1996-04-16
ES2070107T5 ES2070107T5 (es) 2004-05-16

Family

ID=20380033

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91913019T Expired - Lifetime ES2070107T5 (es) 1990-07-23 1991-07-22 Ensayo de antigeno especifico de la prostata (psa) libre y complejado.

Country Status (10)

Country Link
US (4) US5501983A (es)
EP (1) EP0540573B2 (es)
JP (1) JP2669566B2 (es)
AT (1) ATE134448T1 (es)
DE (2) DE69117292T3 (es)
DK (1) DK0540573T4 (es)
ES (1) ES2070107T5 (es)
GR (1) GR3019888T3 (es)
SE (1) SE9002480D0 (es)
WO (1) WO1992001936A1 (es)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965379A (en) * 1991-07-19 1999-10-12 Cytimmune Sciences Inc. Method for measuring endogenous cytokines
GB9309966D0 (en) * 1993-05-14 1993-06-30 Nordion Int Inc Detection of prostrate-specific antigen in breast tumors
GB9314623D0 (en) * 1993-07-14 1993-08-25 Nordion Int Inc Localization and therapy with agents directed against prostate specific antigen in breast cancer
EP0635575A1 (en) 1993-07-22 1995-01-25 Wallac Oy Monoclonal antibodies against epitopes found in free but not in alpha-1-antichmotrypsin complexed prostate specific antigen
EP0652014A1 (en) * 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
US5599677A (en) * 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
GB9415489D0 (en) * 1994-08-01 1994-09-21 Nordion Int Inc Detection of prostate-specific antigen in amniotic fluid
EP0725139A3 (en) * 1995-02-03 1997-11-26 Bayer Corporation Recombinant prostate-specific antigen and its use as an immunoassay calibrator
US5698402A (en) * 1995-02-23 1997-12-16 Dianon Systems, Inc. Methods for diagnosing benign prostatic hyperplasia
US5614372A (en) * 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
US5654161A (en) * 1995-05-12 1997-08-05 Chiron Diagnostics Corporation Method for diagnosing prostate cancer
US5807978A (en) * 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US5800347A (en) * 1995-11-03 1998-09-01 The General Hospital Corporation ROC method for early detection of disease
EP0957749A2 (en) * 1995-09-12 1999-11-24 The General Hospital Corporation Method for early detection of ovarian cancer
US5710007A (en) * 1995-09-29 1998-01-20 Luderer; Albert A. Methods for diagnosing prostatic adenocarcinoma
EP0855910A4 (en) * 1995-10-18 2000-07-05 Merck & Co Inc Conjugates that can be used to treat benign prostate hyperplasia
EP0789032A2 (en) * 1996-02-01 1997-08-13 Bayer Corporation Method for preparing a monoclonal antibody that provides an equimolar response to free and complexed analyte in a monoclonal/polyclonal sandwich immunoassay
US6143509A (en) * 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
AU775537B2 (en) * 1996-04-26 2004-08-05 Children's Medical Center Corporation Non-invasive enzyme screen for tissue remodelling-associated conditions
US6811995B1 (en) 1996-04-26 2004-11-02 Children's Medical Center Corporation Non-invasive enzyme screen for cancer
JP2000510949A (ja) * 1996-04-26 2000-08-22 チルドレンズ メディカル センター コーポレーション 組織のリモデリングに関連した状態のための非観血的酵素スクリーン
AU4086397A (en) * 1996-09-06 1998-03-26 Centocor Inc. Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen
DE19641560A1 (de) * 1996-10-09 1998-04-16 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen einen Komplex aus humanem ACT und einer Serinprotease
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US6107103A (en) * 1996-10-15 2000-08-22 Procyon Bropharma Inc. Assay for PSP94 protein
IL121659A (en) * 1996-10-25 2000-07-16 Bayer Ag Method for determining CPSA in a blood sample
US5840501A (en) * 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
US5856182A (en) * 1996-11-18 1999-01-05 Beckman Coulter, Inc. Monoclonal antibodies specific for the PSA-ACT complex
US6548260B1 (en) 1997-01-21 2003-04-15 Bayer Corporation Detection of PSA-α2-macroglobulin complex in a biological fluid
US6309816B1 (en) * 1997-04-16 2001-10-30 Horus Therapeutics, Inc. Methods for diagnosing cancer by measuring creatine kinase
DE19717436C2 (de) * 1997-04-25 2001-02-15 Biomac Gmbh Verfahren zur exakten Bestimmung von Prostata-spezifischem Antigen in Körperflüssigkeiten
US7288636B2 (en) * 1997-04-30 2007-10-30 Hybritech Incorporated Forms of prostate specific antigens and methods for their detection
EP0983509B1 (en) * 1997-05-14 2005-08-17 Biosite Diagnostics Inc. Rapid evaluation of the ratio of biological molecules
US5994085A (en) * 1997-08-26 1999-11-30 Cantor; Thomas L. Methods and devices for detecting non-complexed prostate specific antigen
US6649420B1 (en) 1997-08-26 2003-11-18 Thomas L. Cantor Methods and devices for detecting no-complexed prostate specific I antigen
US6300088B1 (en) 1997-11-24 2001-10-09 Duke University Method of detecting prostate specific antigen
DE19814915A1 (de) * 1998-04-03 1999-10-07 Roche Diagnostics Gmbh Immunologisches Verfahren zur Bestimmung von PSA
FI981186A7 (fi) 1998-05-28 1999-11-29 Stenman Ulf Haakan Uusi immunomääritys ja sen käyttö diagnostiikassa
FI981185A7 (fi) * 1998-05-28 1999-11-29 Stenman Ulf Haakan Uusi diagnostinen menetelmä
US7226731B1 (en) 1998-07-24 2007-06-05 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services PB 39, a gene dysregulated in prostate cancer, and uses thereof
EP1100903A1 (en) * 1998-07-24 2001-05-23 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Pb 39, a gene dysregulated in prostate cancer, and uses thereof
DE69934694T2 (de) 1998-08-10 2007-10-04 Agensys, Inc., Santa Monica Bpc-1: ein ausgeschiedenes gehirnspezifisches protein das von prostata- und blasen-krebszellen exprimiert und ausgeschieden wird
CA2370749A1 (en) 1999-04-20 2000-10-26 Target Discovery, Inc. Polypeptide fingerprinting methods, metabolic profiling, and bioinformatics database
US6423503B1 (en) * 1999-04-30 2002-07-23 Hybritech Incorporated Forms of free prostate-specific antigen (PSA) and their association with prostate tissues from prostate peripheral zone and transition zone
US6893818B1 (en) * 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
FR2807438B1 (fr) * 2000-04-10 2004-09-17 Bio Merieux Nouveaux anticorps reconnaissant specifiquement le psa libre inactif, et leurs applications
GB0012718D0 (en) * 2000-05-24 2000-07-19 Angeletti P Ist Richerche Bio Conjugates of aminodrugs
FR2810114B1 (fr) * 2000-06-13 2002-08-23 Bio Merieux Methode, procede, test immunologique et kit de diagnostic d'un adenocarcinome de la prostate ou d'une hypertrophie benigne de la prostate
DK1299727T3 (da) 2000-07-12 2009-06-15 Agensys Inc Hidtil ukendt tumorantigen, der er egnet til diagnosticering og behandling af blære-, ovarie-, lunge-, og nyrecancertyper
EP1178317B1 (en) 2000-07-24 2004-11-10 Health Research, Inc. Method for detection of prostate specific membrane antigen in serum
US6379550B1 (en) 2000-07-24 2002-04-30 Health Research, Inc. Method for detecting PSA and its molecular forms using thiophilic gel
US6984494B2 (en) * 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
EP1311675B1 (en) 2000-08-22 2007-02-07 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
CA2705366A1 (en) 2000-08-28 2002-03-07 Agensys, Inc. Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
US6764825B1 (en) * 2000-10-13 2004-07-20 Tang J. Wang Methods and device for detecting prostate specific antigen (PSA)
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
EP2287186B1 (en) 2001-09-06 2014-12-31 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7842498B2 (en) 2001-11-08 2010-11-30 Bio-Rad Laboratories, Inc. Hydrophobic surface chip
US7534580B2 (en) * 2002-05-01 2009-05-19 Ambrilia Biopharma Inc. PSP94 diagnostic reagents and assays
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US20040176577A1 (en) * 2002-09-10 2004-09-09 Eva Rojer Immunoassays for specific determination of SCCA isoforms
AU2003296925A1 (en) * 2002-11-01 2004-06-07 Leucadia Technologies, Inc. Displacement sandwich immuno-pcr
EP1565200A4 (en) 2002-11-27 2009-06-24 Agensys Inc NUCLEIC ACID 24P4C12 AND CORRESPONDING PROTEIN FOR THE TREATMENT AND DETECTION OF CANCER
JP2007524361A (ja) 2003-02-10 2007-08-30 アジェンシス， インコーポレイテッド 膀胱癌及びその他の癌の治療及び検出に有用な名称１５８ｐ１ｄ７の核酸及び対応タンパク質
WO2004094652A2 (en) * 2003-04-22 2004-11-04 Neurobiotex, Inc. Zinc-based screening test and kit for early diagnosis of prostate cancer
CA2526274C (en) 2003-05-30 2015-12-01 Agensys, Inc. Prostate stem cell antigen (psca) variants and subsequences thereof
NZ551627A (en) 2004-05-28 2010-02-26 Agensys Inc Antibodies and related molecules that bind to PSCA proteins
DE102004027429B4 (de) 2004-06-04 2018-09-13 Siemens Healthcare Diagnostics Gmbh Verfahren zur Anwendung von auf Markerwerten basierenden Dichtekarten bei der Diagnose von Patienten mit Krankheiten insbesondere von Tumoren
EP2302078B1 (en) * 2004-11-03 2015-07-15 Iris Molecular Diagnostics, Inc. Microbubbles for affinity concentration
DK1842226T3 (da) * 2004-11-03 2010-10-18 Iris Molecular Diagnostics Inc Homogen analytpåvisning
US8663600B2 (en) * 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
US20080125582A1 (en) * 2006-10-13 2008-05-29 Bio-Rad Laboratories, Inc. Methods and compositions for stabilizing prostate specific antigen
US20090088981A1 (en) * 2007-04-26 2009-04-02 Neville Thomas B Methods And Systems Of Dynamic Screening Of Disease
JP5305361B2 (ja) 2007-05-04 2013-10-02 オプコ・ダイアグノスティクス・リミテッド・ライアビリティ・カンパニー 流体コネクタおよびマイクロ流体システム
US20090087860A1 (en) * 2007-08-24 2009-04-02 Todd John A Highly sensitive system and methods for analysis of prostate specific antigen (psa)
US8362325B2 (en) 2007-10-03 2013-01-29 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated plant characteristics
CN103884840A (zh) * 2008-02-21 2014-06-25 艾瑞斯国际有限公司 早期确定前列腺癌治疗后复发的方法
US8538778B2 (en) * 2008-05-15 2013-09-17 Soar Biodynamics, Ltd. Methods and systems for integrated health systems
US20100168621A1 (en) * 2008-12-23 2010-07-01 Neville Thomas B Methods and systems for prostate health monitoring
WO2010078554A1 (en) 2009-01-05 2010-07-08 Bio-Rad Laboratories, Inc. Process design using mass spectrometry
DK2391451T3 (en) 2009-02-02 2018-10-15 Opko Diagnostics Llc STRUCTURES FOR MANAGING LIGHT INTERACTION WITH MICROFLUIDIC DEVICES
EP2239675A1 (en) 2009-04-07 2010-10-13 BIOCRATES Life Sciences AG Method for in vitro diagnosing a complex disease
CN102346536A (zh) * 2010-07-29 2012-02-08 元太科技工业股份有限公司 省电触控电子书
CN103443628A (zh) 2011-03-28 2013-12-11 积水医疗株式会社 Psa测定方法及其试剂
WO2013063312A1 (en) 2011-10-25 2013-05-02 Memorial Sloan-Kettering Cancer Center Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer
WO2013086499A2 (en) 2011-12-09 2013-06-13 Ceres, Inc. Transgenic plants having altered biomass composition
MY193914A (en) 2012-03-05 2022-11-01 Oy Arctic Partners Ab Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
DK3123381T3 (da) 2014-03-28 2023-11-27 Opko Diagnostics Llc Sammensætninger og fremgangsmåder relateret til diagnose af prostatacancer
WO2016160545A1 (en) 2015-03-27 2016-10-06 Opko Diagnostics, Llc Prostate antigen standards and uses thereof
CN108802392A (zh) * 2018-08-29 2018-11-13 上海市东方医院 一种用于诊断前列腺癌的层析试纸条及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001849A1 (en) * 1979-12-28 1981-07-09 Research Corp Purified human prostate antigen
US4446122A (en) * 1979-12-28 1984-05-01 Research Corporation Purified human prostate antigen
US4690890A (en) * 1984-04-04 1987-09-01 Cetus Corporation Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay
AU602861B2 (en) * 1985-03-29 1990-11-01 Hybritech Incorporated Processes for the stabilization of prostate specific antigen in natural matrices
JPH0690203B2 (ja) * 1985-08-23 1994-11-14 中外製薬株式会社 前立腺特異抗原とα▲下１▼−アンチトリプシン複合体の定量方法
US5599677A (en) * 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides

Also Published As

Publication number Publication date
DE540573T1 (de) 1995-09-28
DE69117292T3 (de) 2004-06-03
DK0540573T4 (da) 2004-04-05
EP0540573A1 (en) 1993-05-12
DE69117292D1 (de) 1996-03-28
US5939533A (en) 1999-08-17
GR3019888T3 (en) 1996-08-31
JP2669566B2 (ja) 1997-10-29
JPH06502719A (ja) 1994-03-24
DK0540573T3 (da) 1996-04-09
ATE134448T1 (de) 1996-03-15
US5501983A (en) 1996-03-26
WO1992001936A1 (en) 1992-02-06
ES2070107T5 (es) 2004-05-16
US5912158A (en) 1999-06-15
EP0540573B1 (en) 1996-02-21
EP0540573B2 (en) 2003-11-19
SE9002480D0 (sv) 1990-07-23
ES2070107T3 (es) 1996-04-16
US20020123616A1 (en) 2002-09-05
DE69117292T2 (de) 1996-07-18

Similar Documents

Publication Publication Date Title
ES2070107T1 (es) Ensayo de antigeno especifico de prostata (psa) libre o complejado.
CY1116265T1 (el) Kit ραδιοεπισημανσης και προσδιορισμος δεσμευσης
DK0914155T3 (da) Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen
DE69535272D1 (de) Polyspezifische immunkonjugate und antikörper zusammensetzungen zur zielgerichteten erkennung des multidrug resistenz phenotyps
DK0749325T3 (da) Bispecifikke molekyler med klinisk anvendelse
ES2171676T3 (es) Inmunoensayos por quimioluminiscencia para la deteccion de anticuerpos.
ES2171219T3 (es) Deteccion precoz de cancer de prostata (cap) por determinacion de una relacion entre las concentraciones de antigeno especifico de prostata (psa) y calicreina glandular humana (hgk-1).
CY1107537T1 (el) Ανaλυση συνδυασμoy hcv αντιγoνου/αντισωματος
DE69731977D1 (de) Spezifische antikörper für dendritische zellen
KR890015714A (ko) 폐암의 조기 검출 방법
CY1116133T1 (el) Κλασματα θρομβοσπονδινης (thrombospondin) και χρησεις αυτων σε κλινικες δοκιμες για καρκινο και δημιουργια αντισωματων και αλλων παραγοντων συνδεσης
ATE197052T1 (de) Topiramate-immunoassay, sowie analoge und antikörper
ES2131690T3 (es) Dispositivo para la dosificacion de haptenos y su utilizacion.
KR890702039A (ko) 1,25-디하이드록시 비타민 d의 분석 방법
MX9401112A (es) Preparacion de conjugados de fotoproteina y metodos para utilizar los mismos.
ATE343597T1 (de) Diagnostisches assay für typ-2-heparin induzierte thrombocytopenie
WO2003046140A3 (en) Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample
FI922017A0 (fi) Immunbestaemningar och monoklonala antikroppar foer protrombinaktiveringspeptider och degradations- produkter av dessa.
MX9708697A (es) Metodo para diagnostico cancer de prostata.
DE60222091D1 (de) Dendritische chemilumineszierende Substrate
CY1110429T1 (el) Προσδιορισμος
ES2168378T3 (es) Determinacion de tripsinogeno-2 libre y en forma de complejo.
YU46858B (sh) Postupak za dobijanje imunoglobulinskih konjugata
DE69529106D1 (de) Monoklonaler Antikörper gegen denThrombin-Antithrombin III-Komplex und dessen Verwendung in Immunoassays
TR199901648T2 (xx) Laminin'in nidojen domenine ba�lanan antikorlar�n �retilmesi ve kullan�m�.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 540573

Country of ref document: ES